What it is
Vesugen is a short peptide bioregulator from the Khavinson literature.
Evidence boundary
Regional literature only. Do not present it as a settled vascular standard.
Trial evidence
- PMID 26390612 — [EFFECT OF SYNTHETIC PEPTIDES ON AGING OF PATIENTS WITH CHRONIC POLYMORBIDITY AND ORGANIC BRAIN SYNDROME OF THE CENTRAL NERVOUS SYSTEM IN REMISSION].
- PMID 25051766 — [Effect of the bioactive peptide Vesugen on the regeneration of the blood-lymph barrier in rats with experimental burn disease].
- PMID 22808515 — [Functional and hemostatic changes in patients with diabetic retinopathy under treatment with the peptide bioregulator vesugen].
- PMID 18546826 — [The effect of the peptide bioregulator Vesugen on endothelial function in patients with ischemic heart disease].
Preparation and measurement
Reconstitution: 20 mg vial + 3 mL BAC = 6.67 mg/mL.
Concentration matches.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Days 1–20 (cycle on) | 500 mcg | 7.5 U (0.075 mL) | Once daily during cycle (20 days on / 4–6 months off) | 3.5 mg/week |
| Months 1–6 (cycle off) | 0 mcg | 0 U (no draw) | Off | 0 |
Days 1–20 (cycle on)
- Dose
- 500 mcg
- Draw / measure
- 7.5 U (0.075 mL)
- Frequency
- Once daily during cycle (20 days on / 4–6 months off)
- Weekly total
- 3.5 mg/week
Months 1–6 (cycle off)
- Dose
- 0 mcg
- Draw / measure
- 0 U (no draw)
- Frequency
- Off
- Weekly total
- 0
Weekly totals apply only during the active phase.
Titration rules
-
Days 1–20 (cycle on): 500 mcg/day. Once daily during the 20-day active phase.
-
Cycle structure: 20-day active phase, 4–6 month rest. 1–2 cycles per year is standard.
-
Timing: Once daily during active phase; time of day flexible. Rotate injection sites.
-
Do not read this as stronger than the evidence supports.
-
Tolerability
-
Injection-site reactions
-
Regional protocol claims only
Practical rules
- Rotate sites if it is being compared in notes.